ReviewWorld journal of gastroenterology2014
Advances in non-surgical management of primary liver cancer.
Review in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- UPLC-Q-TOF-MS/MS Profiling and Synergistic Anti-HCC Activity of Gallic Acid From Compound Muji Granules Combined With hUC-MSC-Exos.Chemistry & biodiversity · 2026Article
- Comprehensive identification and validation of hub genes targeted by quercetin in hepatocellular carcinoma via integrated bioinformatics and experimental approaches.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- HAIC-Based versus TACE-Based Triple Therapy with Lenvatinib and PD-1 Inhibitors for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Retrospective Propensity Score-Matched Study.Journal of hepatocellular carcinoma · 2026Article
- ZIF-8 Nanocarrier-Based Co-Delivery of Curcumin and 5-Fluorouracil for Synergistic Antitumor Activity in Hepatocellular Carcinoma.International journal of general medicine · 2026Article
- A Prognostic Risk Model for Hepatocellular Carcinoma Integrating Ferroptosis and Metabolic Reprogramming Signatures.Journal of Cancer · 2026Article
- A Network Phenotyping Strategy approach in a Turkish HCC Dataset and Comparison of Patients Selected for Transplant and those who were not.Journal of Inonu Liver Transplantation Institute · 2025Article
- Tolerability and Effectiveness of Regorafenib Treatment in Patients with Unresectable Hepatocellular Carcinoma: Real-World Data from the United States.Journal of hepatocellular carcinoma · 2025Article
- Immunotherapy and liver cancer research trends and the 100 most cited articles: A bibliometric analysis.Technology and health care : official journal of the European Society for Engineering and Medicine · 2024Article
- Glycyrrhetinic Acid Receptor-Mediated Zeolitic Imidazolate Framework-8 Loaded Doxorubicin as a Nanotherapeutic System for Liver Cancer Treatment.Molecules (Basel, Switzerland) · 2023Article
- The progress of research on immune checkpoint inhibitor resistance and reversal strategies for hepatocellular carcinoma.Cancer immunology, immunotherapy : CII · 2023Review
- Trends in medical care utilization in patients with cancer: An analysis of real-world data in a tertiary hospital in Korea, 2014-2019.Cancer medicine · 2023Article
- Observational
- Proteomic quantification of receptor tyrosine kinases involved in the development and progression of colorectal cancer liver metastasis.Frontiers in oncology · 2023Article
- Quantitative Proteomics of Hepatic Drug-Metabolizing Enzymes and Transporters in Patients With Colorectal Cancer Metastasis.Clinical pharmacology and therapeutics · 2022Article
- A Panel of E2F Target Gene Signature Predicting the Prognosis of Hepatocellular Carcinoma.Frontiers in genetics · 2022Article
- Identification of DNA repair-related genes predicting pathogenesis and prognosis for liver cancer.Cancer cell international · 2021Article
- "Homomorphic" Tumor Metastases as an Endodiagnostic Clue: A Case Series of Renal-Cell Carcinoma Metastatic to the Stomach.Gastrointestinal tumors · 2019Article
- Ginsenoside Rg3 Prolongs Survival of the Orthotopic Hepatocellular Carcinoma Model by Inducing Apoptosis and Inhibiting Angiogenesis.Analytical cellular pathology (Amsterdam) · 2019Article
- Yu Ping Feng San Exert Anti-Angiogenesis Effects through the Inhibition of TSLP-STAT3 Signaling Pathways in Hepatocellular Carcinoma.Evidence-based complementary and alternative medicine : eCAM · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third most common cause of cancer-related death worldwide. There have been great improvements in the diagnosis and treatment of HCC in recent years, but the problems, including difficult diagnosis at early stage, quick progression, and poor prognosis remain unsolved. Surgical resection is the mainstay of the treatment for HCC. However, 70%-80% of HCC patients are diagnosed at an advanced stage when most are ineligible for potentially curative therapies such as surgical resection and liver transplantation. In recent years, non-surgical management for unrespectable HCC, such as percutaneous ethanol injection, percutaneous microwave coagulation therapy, percutaneous radiofrequency ablation, transcatheter arterial chemoembolization, radiotherapy, chemotherapy, biotherapy, and hormonal therapy have been developed. These therapeutic options, either alone or in combination, have been shown to control tumor growth, prolong survival time, and improve quality of life to some extent. This review covers the current status and progress of non-surgical management for HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.